AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

Core Insights - AbbVie is committed to advancing standards of care in inflammatory bowel diseases (IBD) by presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, including three oral presentations focused on Crohn's disease and ulcerative colitis [1][2][30] Group 1: Research and Presentations - The SEQUENCE trial will present data comparing the efficacy of risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease, including an economic analysis and inflammation biomarkers [1][3] - Additional studies will evaluate the efficacy and safety of risankizumab in both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study for ulcerative colitis [1][3] - Notable presentations include the achievement of clinical remission and reduction in inflammatory biomarkers in patients with moderate-to-severe Crohn's disease from the Phase 3b SEQUENCE Trial [5] Group 2: Company Strategy and Commitment - AbbVie aims to enhance the understanding of IBD and improve patient outcomes by building a diverse portfolio of marketed and investigational products [2][30] - The company emphasizes the importance of addressing both acute needs and long-term care goals for IBD patients, showcasing its leadership in gastroenterology [2][30] - AbbVie is focused on driving discoveries and advancing science to elevate the standards of care for individuals living with IBD [2][30]